CA-POINT2WEB
31.7.2024 18:54:28 CEST | Business Wire | Press release
Point2Web, your ultimate marketing powerhouse in creative, advertising, and performance marketing, is thrilled to announce its appointment as the first Agency Sales Partner in Europe for NewsBreak, America's leading platform for local news and information, with over 40 million monthly active users.
Together, Point2Web and NewsBreak are poised to deliver exceptional advertising solutions that deeply engage local audiences. This partnership aims to drive significant growth and performance for Point2Web clients by combining the strengths of both companies to create something truly groundbreaking. The collaboration is expected to foster innovation, enhance service excellence, and achieve positive results for NewsBreak’s local users and their communities across America.
By utilizing NewsBreak's innovative technology and unrivaled local footprint, brands can revolutionize their local and targeted advertising and help direct resources where they are needed most. Point2Web's industry-leading expertise will further enable clients to amplify their advertising impact on an unprecedented scale. The collaboration will be particularly beneficial to advertisers in insurance, finance, travel, home improvement, e-commerce, and casual gaming, among others.
Partnership Highlights:
- Extended Reach: Point2Web clients will now have access to NewsBreak's 40 million users across the U.S., significantly enhancing the impact of their advertising campaigns. This access ensures advertisers can reach a vast yet highly engaged user base.
- Innovative Solutions: The partnership brings NewsBreak's use of new technology to Point2Web's clientele.
- Global Expertise, Local Impact: Point2Web's global presence and deep expertise in performance networks, combined with NewsBreak's robust local information platform, ensures a targeted and effective advertising strategy that will resonate with local communities. This synergy enables advertisers to craft messages that are both globally informed and locally relevant.
- Fostering Innovation and Achieving Success: Both Point2Web and NewsBreak share a strong commitment to innovation, excellence in service, and achieving positive results for their stakeholders. This partnership is a testament to their joint vision of pushing the boundaries of what is possible in digital advertising.
“Through our partnership with NewsBreak, we’re not just expanding the digital footprint of our clients; we’re providing them with the tools and platforms necessary to achieve unprecedented levels of engagement and success in their advertising campaigns,” said Valentine Kovalenko, COO at Point2Web. “This collaboration is a testament to our unwavering commitment to innovation and excellence in service. NewsBreak’s audience is highly engaged and of high quality, which ensures that our clients' ads reach a valuable and responsive demographic.”
“We are thrilled to partner with Point2Web, whose global expertise and innovative approach align perfectly with our mission to create a local media ecosystem where information is readily available and easily accessible," said Ryan Ludlow, General Manager of NewsBreak Advertising. "By leveraging our cutting-edge new technology and working with strategic partners like Point2Web, we remain dedicated to enhancing advertiser success and maintaining our focus on ad quality.”
For more information about this partnership and how it can benefit your advertising strategies, please visit our website.
About Point2Web
Point2Web is a global advertising agency that specializes in performance marketing and exceptional creative development. We unite media buying, creative development, and agency access to top-tier ad platforms to provide a powerful blend of services, expertise, and exclusive partnerships around the globe.
Our dedication to excellence and innovation is evident in every project we undertake. Our brand is anchored by our core values: reliability, mutual trust, top-tier service, steadfast commitment, and unending innovation. As we expand our horizons, Point2Web is committed to transparency, integrity, and achieving superior results for our clients.
We redefine the standard with our forward-thinking mindset and the latest in technology, setting new benchmarks in creativity. With a footprint in nine countries, advertisers and publishers worldwide can benefit from our unwavering commitment to driving their growth.
About NewsBreak
NewsBreak is the leading platform for local news and information in the United States, providing users with the local news and information they want and need in a digital form. By using cutting-edge technology that learns users’ preferences to curate tailored content for them, NewsBreak gathers community-focused news and information from over 10,000 sources in a timely, accessible, and easy-to-use way at no cost to users. NewsBreak is bridging the gap between new technology and traditional local media, offering an innovative digital solution that benefits everyone, from individual users and their communities to businesses across America.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240729481955/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom